| 36.955 0.395 (1.08%) | 04-22 15:25 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 46.24  |
1-year : | 54 |
| Resists | First : | 39.59 |
Second : | 46.24 |
| Pivot price | 34.59  |
|||
| Supports | First : | 33.15 |
Second : | 29.17 |
| MAs | MA(5) : | 36.59 |
MA(20) : | 35.29 |
| MA(100) : | 41.46 |
MA(250) : | 43.11 |
|
| MACD | MACD : | -0.5 |
Signal : | -1 |
| %K %D | K(14,3) : | 87.1 |
D(3) : | 81.5 |
| RSI | RSI(14): 53.3 |
|||
| 52-week | High : | 62.4 | Low : | 29.17 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RVMD ] has closed below upper band by 19.0%. Bollinger Bands are 15.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 37.92 - 38.1 | 38.1 - 38.28 |
| Low: | 35.48 - 35.71 | 35.71 - 35.93 |
| Close: | 36.14 - 36.5 | 36.5 - 36.86 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Sun, 20 Apr 2025
Revolution Medicines to Participate in April 2025 Investor Conferences - GlobeNewswire
Mon, 31 Mar 2025
Revolution Medicines to Participate in April 2025 Investor Conferences - GlobeNewswire
Mon, 31 Mar 2025
Revolution Medicines Brings Groundbreaking RAS Cancer Research to Major Healthcare Forums - Stock Titan
Sun, 30 Mar 2025
Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy? - Yahoo Finance
Thu, 06 Mar 2025
Is Revolution Medicines, Inc. (RVMD) Among Stocks With At Least $20 Million In Insider Spending Recently? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 186 (M) |
| Shares Float | 168 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 106.3 (%) |
| Shares Short | 16,650 (K) |
| Shares Short P.Month | 14,920 (K) |
| EPS | -3.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.7 % |
| Return on Equity (ttm) | -29.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -3.19 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -557 (M) |
| Levered Free Cash Flow | -348 (M) |
| PE Ratio | -10.38 |
| PEG Ratio | 0 |
| Price to Book value | 3.04 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|